Takeda Invests in AI‑Based Drug Discovery with Insilico Medicine

The collaboration between Takeda and Insilico Medicine may not have a direct impact on ABBV shares. However, investment in AI-based drug discovery within the sector could positively reflect on the industry in the long term. In the short term, ABBV shares have increased by 2.14% in the last 24 hours, with an RSI14 value of 74.74, indicating a high level. This could increase the likelihood of a short-term correction. Nevertheless, as the direct impact of the news is expected to be limited, a neutral approach seems more appropriate.

The news may increase interest in AI-based discoveries in the pharmaceutical sector, which includes BMY. Technical indicators show that while the RSI is in neutral territory at 61, the MACD is above its signal line and the price is trading above the 20- and 50-day moving averages, suggesting short-term upside potential. However, since the news is not directly related to BMY, the impact may be limited. A slight upward trend can be expected based on the last closing price.

The news announces a collaboration between Takeda and Insilico Medicine, which is neither a direct partner nor a competitor of MRK. Therefore, it is not expected to have a direct impact on MRK's stock. Although technical indicators suggest a slight upward trend (RSI at 62.7, positive MACD, price above SMAs), momentum is limited and there is no clear catalyst. In the short term, the price is likely to move sideways or experience slight fluctuations at current levels.

GSK shares are technically in a short-term uptrend, with the RSI at 65, not yet approaching overbought territory. The MACD is positive and above the signal line, while the price is trading above both the 20-day and 50-day moving averages. However, the news headline is not directly related to GSK but reflects an AI investment trend in the sector. Therefore, the short-term impact may be limited, and the upside expectation has low reliability.